SOPHiA GENETICS (NASDAQ:SOPH) Announces Earnings Results

SOPHiA GENETICS (NASDAQ:SOPH) announced its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, hitting the consensus estimate of ($0.23), Zacks reports. SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. SOPHiA GENETICS updated its FY 2025 guidance to EPS.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock opened at $3.57 on Tuesday. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12. The firm has a fifty day simple moving average of $3.58 and a 200-day simple moving average of $3.56. The stock has a market capitalization of $233.39 million, a price-to-earnings ratio of -3.28 and a beta of 1.03. SOPHiA GENETICS has a 1-year low of $2.70 and a 1-year high of $7.37.

Analyst Upgrades and Downgrades

Separately, Craig Hallum initiated coverage on shares of SOPHiA GENETICS in a research report on Wednesday, December 18th. They set a “buy” rating and a $11.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $7.40.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.